Another setback for Discovery Labs' Surfaxin in Phase II for ARF
This article was originally published in Scrip
Executive Summary
Discovery Laboratories' troubled synthetic lung surfactant Surfaxin (lucinactant) has failed to show signs of efficacy in a Phase II study investigating it for decreasing the duration of mechanical ventilation in children with acute respiratory failure (ARF).